NuVasive (NSDQ:NUVA) announced that it received FDA 510(k) clearance for its Modulus ALIF and Cohere TLIF-O offerings for thoracolumbar procedures.

The San Diego-based company expanded its Advanced Materials Science (AMS) implant portfolio with the clearances, along with the commercial launch of the Modulus extreme lateral interbody fusion (XLIF) dual-sided plate.

NuVasive’s Modulus anterior lumbar interbody fusion (ALIF) porous titanium implant is designed for use in both supine and lateral ALIF and is now the company’s first AMS offering on the ALIF market.

The Cohere transforaminal lumbar interbody fusion (TLIF-O) is a porous implant with NuVasive’s single-step insert and rotate technique, along with a lordotic design in the oblique plane for surgeons to restore sagittal alignment of the spine and avoid undesired coronal misalignment, according to a news release.

NuVasive’s Modulus XLIF dual-sided plate is a low-profile, anti-migration plate designed to allow for two points of fixation in XLIF surgeries, offering individualized solutions at the discretion of the surgeon.

“With these new offerings, NuVasive strengthens its AMS portfolio to equip surgeons with best-in-class technology for a variety of thoracolumbar procedures,” NuVasive president Matt Link said in the news release. “NuVasive’s continued R&D initiatives underscore the company’s commitment to expand within key procedural spine segments and deliver differentiated technology to support better patient outcomes.”